Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya

• Status: Completed
• Trial end date: 2018-10-30
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine whether in RRMS patients receiving Gilenya there is a link between disease progression and biologic markers.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: McGill University
• Collaborator: Novartis
• Treatments: Fingolimod Hydrochloride

Criteria

Inclusion Criteria:

• Deemed by the subject's treating physician to be a suitable candidate for Gilenya therapy in accordance with the Canadian Product Monograph for Gilenya

• has an overall EDSS not above 7.0

• is not currently receiving Gilenya

• is able to perform adequately for EDSS assessment and cognitive tests

• is able to undergo a MRI

• is able to provide blood samples

Exclusion Criteria:

• is over 65 years of age and under 18 years of age

• has less than 4 weeks of discontinuation with steroid treatment for a relapse.